David Hung
About David Hung
David Hung's Role as Founder and CEO of Medivation
David Hung served as the Founder, President, and Chief Executive Officer of Medivation, Inc., which he established in 2003. Under his leadership, Medivation raised a total of $433 million through public offerings and achieved a market capitalization surpassing $14 billion. In a notable transaction, Medivation was sold to Pfizer for $14.3 billion in 2016, marking a significant milestone in the biotechnology and pharmaceuticals industry.
Development of Enzalutamide (XTANDI®) for Prostate Cancer
David Hung played a pivotal role in identifying, in-licensing, and leading the development of enzalutamide (XTANDI®), a treatment for advanced prostate cancer. He managed the project from its initial in vitro laboratory experiments to obtaining FDA approval within seven years. This rapid development timeline was crucial for patients suffering from advanced prostate cancer, offering a new and effective treatment option.
Achievements in Drug Development: Talazoparib and Pidilizumab
Under David Hung's guidance, Medivation also developed talazoparib, a potentially best-in-class PARP inhibitor, which received FDA approval in October 2018. Additionally, he oversaw the development of the immune-oncology agent pidilizumab, which displayed robust effects in Phase 2 studies. These achievements highlight his significant contributions to oncology and the development of breakthrough therapeutics.
David Hung's Academic Background in Medicine and Research
David Hung earned an A.B. summa cum laude in biology from Harvard College and an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine. He completed simultaneous clinical fellowships in hematology, oncology, and transfusion medicine, along with two basic science research fellowships in molecular biology, all at UCSF. His comprehensive education and advanced fellowships underscore his expertise and foundational knowledge in medical science and research.
Leadership Experience and Innovations at ProDuct Health
Before his tenure at Medivation, David Hung served as President and Chief Executive Officer of ProDuct Health, Inc. During his time there, he invented a breast microcatheter aimed at assessing breast cancer risk. ProDuct Health was subsequently acquired by Cytyc Corporation for $168 million. This acquisition and his innovative contributions further demonstrate his capability in leading biotech companies and advancing medical technologies.